Astellas and AI Proteins sign miniprotein therapeutics deal
AI Proteins is to receive an upfront sum to design and optimise de novo miniproteins selected by Astellas.
Drug Development
MSD’s Keytruda and Padcev combination receives EC approval
FDA approves Cosette’s Evoxac oral solution for Sjögren’s disease
Sanofi and ScionxBio partner on mRNA therapies
FDA approves Viatris’ Ryzumvi for adult presbyopia
Estuary secures $103m to advance kidney disease gene therapies
Acta Pharmaceuticals raises $24m for Alzheimer’s therapies
Transcripta Bio, Mayo Clinic join force on ALS therapies
